Generon Receives Special Protocol Assessment for Global Phase 3 Trial of F-627 in … | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado
The only conference focused solely on the pharmaceutical development of peptide therapeutics.
MENU

Generon Receives Special Protocol Assessment for Global Phase 3 Trial of F-627 in …

Generon Receives Special Protocol Assessment for Global Phase 3 Trial of F-627 in …
Peptide News from Biotech and Pharma, Raw News October 10, 2017

SHANGHAI, China I October 10, 2017 I Generon Corporation, an innovative biopharmaceutical company in China developing novel biological ...

Email

support@boulderpeptide.org

s2Member®
loading...